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A 45-year-old man with stage IVA thymic carcinoma was enrolled on a phase II study of sunitinib (50 mg daily)1 
4 weeks after disease progression on first-line chemotherapy 
with cisplatin, doxorubicin, cyclophosphamide, and belino-
stat.2 Molecular profiling of the tumor revealed only a p53 
gene mutation (c-Kit was wild type).3
Baseline chest computed tomography, before sunitinib, 
showed a mediastinal mass with compression of the proxi-
mal right main pulmonary artery (Fig. 1A) and direct invasion 
of pericardium. Three weeks after initiation of sunitinib, the 
patient reported increased left shoulder pain, cough, nausea, 
vomiting, and a palpable soft and fluctuating lesion measuring 
2 cm in size overlying the sternum. A new computed tomog-
raphy scan (Fig. 1B–D) showed an increase in the size of the 
mediastinal mass, which now included air (Fig. 1B–D, aster-
isk), air-fluid levels (Fig. 1B, D, arrow), dissection in the ante-
rior chest wall with subcutaneous air (Fig. 1C, double arrow), 
and a large left pleural effusion (Fig. 1B–D). Sunitinib was dis-
continued, and a thoracentesis was performed to remove a liter 
of straw-colored fluid. Considering disease progression with 
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FIGURE 1. (A) Bulky mediastinal mass on CT scan, without contrast, before sunitinib; (B–D) mediastinal mass containing air 
(asterisk), air-fluid levels (arrow), with dissection in the anterior chest wall and subcutaneous air (double arrow), and large left 
pleural effusion after 3 weeks of sunitinib. CT, computed tomography.
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tumor necrosis and superimposed infection with the possibil-
ity of bronchocutaneous fistula, antibiotic therapy was started. 
Subsequently, the patient’s clinical condition deteriorated rap-
idly with development of right ventricular heart failure, and he 
died 2 weeks later. The autopsy revealed massive neoplastic 
infiltration of the heart and great vessels, including the pulmo-
nary artery and left lung, with abundant tumor necrosis, most 
likely related to rapid progression of disease rather than anti-
angiogenesis effects of sunitinib. This represents an unusual 
finding in a patient with an aggressive thymic carcinoma.
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